Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.08.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Alesa Campbell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Medical Center Department of Pharmacy, Center for Transplantation, Bronx, NY, USA. Hauptthemen laut MEDLINE: Hyperkalemia, Kidney Transplantation, Potassium, Postoperative Complications. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Evaluate the safety/efficacy of novel potassium binders (patiromer, sodium zirconium cyclosilicate [SZ-9]) for early postoperative hyperkalemia following kidney transplantation. METHODS: Retrospective, single-center, cohort study of deceased-donor kidney recipients transplanted between 1/2018 and 12/2020. Potassium-binder use was evaluated from immediately posttransplant until discharge. Potassium binders were administered ≥2 hours before/after medications. RESULTS: A total of 179 patients were included, 24 (13%) of whom received potassium binders (16 [67%] patiromer, 7 [29%] SZ-9, 1 [4%] both) for a mean of 2.5 (±3.18) doses. Peak potassium levels were higher in the potassium-binder group (6.05 vs 5.35 mEq/L; P < .001). More patients on potassium binders transitioned to atovaquone than those on no binders (n = 21 [100%] vs n = 112 [75%], respectively; P = .005). Delayed graft function (DGF) was observed in 100 (56%) patients, with a higher proportion receiving potassium binders (18 [75%] vs 82 [53%], respectively; P = .042). There was no difference between groups in number of posttransplant dialysis sessions required in the general study population (P = .2), nor in the DGF group (P = .12). No difference was noted in the incidence of ileus (P = .2), or gastrointestinal symptoms (diarrhea, nausea, vomiting; P = .6). Of the 24 patients who received inpatient binders, 9 (37.5%) were discharged and remained on them for a mean of 46 (±49) days. CONCLUSION: Patiromer and SZ-9 appear safe in the early posttransplant period, but larger prospective trials are needed. Potassium-binder use does not appear to be associated with fewer dialysis sessions in DGF patients, however, they may be used as additional tools for lowering potassium in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Montefiore Medical Center Department of Pharmacy, Center for Transplantation, Bronx, NY, USA.
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Montefiore Medical Center, Albert Einstein College of Medicine Abdominal Transplant Center, Bronx, NY, USA.
- Department of Population Health Sciences, Weill Cornell Medicine Division of Biostatistics, New York, NY, USA.
- Montefiore Medical Center, Albert Einstein College of Medicine Abdominal Transplant Center, Bronx, NY, USA. Electronic address: majaimy@montefiore.org.
Zitieren
APA
Campbell, A., Xiao, W., Akalin, E., Azzi, Y., Liriano-Ward, L., Pynadath, C., Graham, J., Hemmige, V., Verzani, Z., & Ajaimy, M. (2024). Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.08.006
Vancouver
Campbell A, Xiao W, Akalin E, Azzi Y, Liriano-Ward L, Pynadath C, et al. Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.08.006
BibTeX
@article{Campbell2024,
author = {Campbell, Alesa and Xiao, Weirui and Akalin, Enver and Azzi, Yorg and Liriano-Ward, Luz and Pynadath, Cindy and Graham, Jay and Hemmige, Vagish and Verzani, Zoe and Ajaimy, Maria},
title = {Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.08.006}
}
EUVIMED